Iradimed (IRMD) Getting Somewhat Favorable Media Coverage, Study Finds

Media stories about Iradimed (NASDAQ:IRMD) have trended somewhat positive on Saturday, Accern Sentiment reports. The research group scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Iradimed earned a coverage optimism score of 0.24 on Accern’s scale. Accern also assigned news headlines about the medical equipment provider an impact score of 47.4377246159722 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Shares of Iradimed (NASDAQ:IRMD) traded down $0.12 during mid-day trading on Friday, hitting $13.30. The company had a trading volume of 2,898 shares, compared to its average volume of 21,771. Iradimed has a 1-year low of $7.85 and a 1-year high of $15.85. The company has a market cap of $141.70, a P/E ratio of 266.00 and a beta of 1.45.

Iradimed (NASDAQ:IRMD) last issued its quarterly earnings data on Tuesday, February 6th. The medical equipment provider reported $0.06 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.02 by $0.04. Iradimed had a return on equity of 3.06% and a net margin of 2.17%. The business had revenue of $6.70 million for the quarter, compared to the consensus estimate of $6.72 million. During the same period last year, the business earned $0.11 EPS. The firm’s revenue was up 11.9% compared to the same quarter last year. sell-side analysts predict that Iradimed will post 0.25 EPS for the current year.

A number of equities research analysts have recently weighed in on the company. Zacks Investment Research raised Iradimed from a “hold” rating to a “buy” rating and set a $17.00 price target for the company in a research note on Wednesday, February 7th. Roth Capital initiated coverage on Iradimed in a research note on Tuesday, October 31st. They issued a “buy” rating and a $16.00 price objective on the stock. Finally, Credit Suisse Group initiated coverage on Iradimed in a research note on Monday, November 27th. They issued a “buy” rating and a $19.00 price objective on the stock. One research analyst has rated the stock with a hold rating and three have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $17.33.

In other Iradimed news, Director Monty K. Allen sold 1,898 shares of the firm’s stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $13.95, for a total value of $26,477.10. Following the sale, the director now owns 9,062 shares of the company’s stock, valued at approximately $126,414.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 60.10% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY WARNING: This piece of content was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://stocknewstimes.com/2018/02/17/iradimed-irmd-getting-somewhat-favorable-media-coverage-study-finds.html.

About Iradimed

IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment.

Insider Buying and Selling by Quarter for Iradimed (NASDAQ:IRMD)

Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply